Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$101.00
neg -0.08
-0.07%
Today's Range: 100.90 - 102.10 | GILD Avg Daily Volume: 13,684,300
Last Update: 03/27/15 - 4:14 PM EDT
Volume: 8,744,358
YTD Performance: 7.23%
Open: $101.00
Previous Close: $101.08
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,489,401,683
Market Cap: 148,731,652,064
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 10 11 12
Moderate Buy 2 2 2 2
Hold 3 3 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.61 1.69 1.65 1.61
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 13.59
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
13.59 13.60 27.33
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.77% 38.88% 328.10%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.13 $2.76 $9.89 $9.39
Number of Analysts 1 1 2 2
High Estimate $3.13 $2.76 $10.64 $10.77
Low Estimate $3.13 $2.76 $9.13 $8.00
Prior Year $1.44 $2.32 $7.91 $9.89
Growth Rate (Year over Year) 117.36% 18.97% 24.97% -5.06%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
If there is no catalyst, I'd join those who sell on a bounce.
It takes a village of positive reports to sustain market.

Investing Amid Turbulence Real Money Pro($)

It looks like it could be stormy in the markets today too.

How I Play the Biotechs Real Money Pro($)

A strategy to immunize biotech investors from regret.
Own them, or take something off the table?
I really like the stocks. But I also like making money on stocks.

The Next Biotech Breakout? Real Money Pro($)

As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami).

Gilead Set Up for a Breakout Real Money Pro($)

There is now a low-risk entry opportunity for GILD bulls.
Amgen and Gilead shine in one of the market's best-performing sectors.
Sector could regain its leadership role.

Columnist Conversations

Darden Restaurant's (DRI) CFO sold 66,863 shares on March 24, 2015 for an average price of $69.68. Proceeds to...
We did not end up holding the pullback to the last time/price low in NFLX. I have run some new price relation...
The Biotech iShares (IBB) fund closed up nearly 2% on the day, but was down over 5% on the week. Today's volu...
Full on breakout for shares of CAG today. The earnings inspired ramp(+5.5%)has it in the number 3 spot o...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.